Vectura Group confirms the announcement by Novartis of positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequently exacerbating patients with moderate COPD from their current treatments, including steroid-containing combinations and long-acting bronchodilators, to the dual bronchodilator Ultibro Breezhaler (indacaterol/glycopyrronium) 110/50 mcg.
In the CRYSTAL study, patients with moderate COPD who were switched to Ultibro Breezhaler from their previous therapy (LABA+ICS or LABA or LAMAo) experienced superior improvements in lung function (trough FEV1) and breathlessnessǂ at week 12 (p<0.0001).
Significantly, CRYSTAL is the first LABA/LAMA pragmatic trial, designed to mimic clinical practice, so treatment switching occurred without a washout period1. Ultibro Breezhaler was also well tolerated in the CRYSTAL study.
At 9:52am: (LON:VEC) Vectura Group PLC share price was +1.9p at 138.8p
Story provided by StockMarketWire.com